LPIXEL
LPIXEL is a Japan-based medical AI company that develops regulated deep-learning image-analysis software (EIRL suite) for radiology, endoscopy, and surgical guidance, serving hospitals and pharmaceutical research customers across Japan and expanding into ASEAN and MENAT markets.
- Company typePrivate
- Founded2014
- HeadquartersOtemachi, Japan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What LPIXEL does
LPIXEL Inc. (エルピクセル株式会社) is a University of Tokyo spin-off founded in March 2014 that develops AI-powered medical image analysis software for clinical diagnostics and pharmaceutical research. Its flagship product family, EIRL, is a suite of regulated Software as a Medical Device (SaMD) products that deploy deep-learning computer vision across brain MRI (aneurysm detection), chest X-ray (lung nodule detection), chest CT, colonoscopy (polyp detection with differential diagnosis), and laparoscopic surgery support. The company also operates IMACEL, an AI platform for drug discovery image analysis, and ImaChek, an automated image-manipulation detection service for scientific publication integrity. The core technology stack comprises proprietary deep-learning models trained on the company's accumulated imaging dataset of more than 12 million cases, with multiple PMDA-approved SaMD products and EN ISO 13485:2016 medical-device quality certification.
The company generates revenue through enterprise SaaS subscriptions, per-case usage pricing, and one-time licenses for certified medical devices, sold through a direct enterprise sales motion targeting Japanese hospitals, complemented by channel partnerships with PACS providers (Jamac System) and medical equipment distributors (Ryukyu Kowa). Customers include more than 1,000 medical institutions across all 47 Japanese prefectures, plus major pharmaceutical companies (Takeda, Astellas, Daiichi Sankyo, Taiho) for drug discovery image analysis. Distribution is increasingly bundled into OEM platforms of Canon Medical Systems (Abierto), Siemens Healthineers (teamplay), NOBORI, M3, and Alamy Join AI Connect, giving LPIXEL reach into installed bases of imaging hardware and PACS networks. Strategic capital partners include Canon Medical Systems, Fujifilm, Olympus, Cyberdyne, and JAFCO, with cumulative disclosed funding of approximately $43 million across Series A (2016), a strategic round (2018), and follow-on capital in 2020 and 2025.
LPIXEL firmographics
Firmographics- Name
- LPIXEL
- Legal name
- エルピクセル株式会社
- Website
- https://lpixel.net
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- LPIXEL is a Japan-based medical AI company that develops regulated deep-learning image-analysis software (EIRL suite) for radiology, endoscopy, and surgical guidance, serving hospitals and pharmaceutical research customers across Japan and expanding into ASEAN and MENAT markets.
- Ownership category
- akta.pro rank
LPIXEL industry classification
Industry- Product category
- Medical Imaging AI / Diagnostic Imaging Software
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Software Publishers (5132)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)
Keywords
Where LPIXEL is headquartered
LocationHeadquarters
- HQ city
- Otemachi
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
LPIXEL business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- SaaS Subscription: Cloud-based subscription model providing AI analysis services to medical institutions on a recurring basis
- Per-Case Pricing: Usage-based pricing where healthcare facilities pay per analysis performed
- Medical Device Sales: Sale of certified medical device software products (EIRL series)
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise institutional licensing |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
LPIXEL product offering
Product offeringCore offering
LPIXEL develops and sells AI-powered medical image diagnostic support software (EIRL series) covering brain MRI, chest X-ray, chest CT, and colonoscopy analysis for hospitals and clinics, as well as the IMACEL cloud platform for AI-assisted drug discovery research and ImaChek for image integrity checking in scientific publications. Products are deployed as regulated Software as a Medical Device (SaMD) with PMDA approval, EN ISO 13485:2016 certification, and integrations with PACS, medical imaging equipment, and cloud platforms.
Differentiator
Problem solved
Functional benefit
Brands
- EIRL (エイル): AI medical image diagnostic support technology for clinical use, including brain MRI, chest X-ray, and colonoscopy analysis.
- IMACEL (イマセル)
- ImaChek (イマチェック)
Products and services
- EIRL Brain Aneurysm AI-powered Software as a Medical Device that analyzes brain MRI images to detect cerebral aneurysms, designed for radiology departments in hospitals and imaging centers.
- EIRL BRAIN AI brain MRI analysis product family for detecting and characterizing brain lesions, used by radiologists in clinical practice.
- EIRL Chest Nodule AI software that detects lung nodule candidate areas from chest X-ray images for radiologist review.
- EIRL Chest Screening Multifunctional chest X-ray AI product integrating lung nodule detection and quantitative chest measurements for screening workflows.
- EIRL Chest CT AI software for detecting lung nodule candidate areas from chest CT images, expanding the EIRL chest product line beyond X-ray.
- EIRL Colon Polyp AI-assisted colonoscopy analysis software that detects colon polyp candidates in real time and assists in colonoscopy procedures, compatible with Olympus and Fujifilm endoscope systems.
- EIRL Viewer Medical imaging display and analysis platform for viewing and interpreting EIRL AI analysis results within clinical workflows.
- EIRL Surgery LC AI-powered landmarking and guidance system for laparoscopic cholecystectomy, supporting minimally invasive surgical procedures.
- IMACEL AI-based image analysis cloud platform for drug discovery and life science research, supporting study design, seeds findings, and evaluation of diseases through phenotypic screening and cell morphology analysis.
- IMACEL Platform Cloud-based image analysis AI platform for drug discovery and academic research, providing efficiency, quality, and safety improvements across the drug development pipeline.
- ImaChek Automated image manipulation and duplication checking system that extracts images from PDF scientific papers and compares them against databases to detect image fraud and honest errors, supporting research integrity.
Quantifiable outcome
- Over 1,000 medical institutions across Japan using LPIXEL solutions
- +2 more outcomes
Companies that use LPIXEL
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
LPIXEL technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
AI capability9 records
Feature5 records
LPIXEL partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered major, core, notable and minor.
- Jameel HealthmajorStrategic collaboration to expand AI medical imaging solutions to MENAT (Middle East, North Africa, Turkey) and Global South markets. Joint go-to-market efforts for healthcare AI deployment.
- Daiichi SankyocoreComprehensive partnership for AI image analysis in pharmaceutical research and drug development. Collaboration focused on applying AI image analysis to support Daiichi Sankyo's drug development pipeline.
- Olympus CorporationcoreStrategic partnership for AI-based landmarking and guidance system for laparoscopic cholecystectomy. Joint development of AI-powered surgical guidance technology for minimally invasive procedures.
- CYBERDYNEnotableBusiness alliance for potential synergies in medical technology and AI solutions. Collaborative exploration of healthcare AI applications.
- NTT DatanotableTechnology partnership for system integration and deployment of AI medical imaging solutions. Collaboration on healthcare IT infrastructure.
- FathomXnotablePartnership for mammography AI development and deployment. Collaboration on breast cancer screening AI solutions.
- TakedacoreAI image analysis partnership for pharmaceutical research and clinical trials. Application of AI to support Takeda's drug development activities.
- Astellas PharmacoreStrategic partnership for AI-powered image analysis in pharmaceutical research. Collaboration on applying AI to Astellas research programs.
- Taiho PharmaceuticalnotableAI image analysis partnership for research applications. Support for Taiho's pharmaceutical research initiatives.
- VNPT-ITminorJoint proof-of-concept initiative in Vietnam for AI medical imaging deployment. Market exploration and pilot programs in Southeast Asia.
- JTECminorJoint proof-of-concept in Vietnam. Collaborative pilot programs for AI medical imaging solutions.
- Tokyo University HospitalcoreAcademic partnership for clinical validation and research collaboration on AI medical imaging technologies. Joint research and product development.
- National Cancer Center JapancoreResearch partnership for cancer screening AI development and clinical validation. Collaborative development of cancer detection AI solutions.
- Jamac SystemnotableDistribution partnership through PACS provider for market access. Integration and resale of LPIXEL AI solutions through medical imaging systems.
- Ryukyu KowaminorDistribution partnership for medical imaging products in regional Japan markets.
Scale indicators5 records
Recent moves8 records
Expansion highlights7 records
LPIXEL competitors and assessment
Company assessmentDirect peers
- AI Medical Service: Tokyo-based medical AI company developing endoscopy/colonoscopy diagnostic support AI. Directly comparable to LPIXEL as a Japanese SaMD-focused medical imaging AI company with PMDA approvals, hospital channel sales, and overlapping colonoscopy product (EIRL Colon Polyp vs. AI Medical Service's endoscopic AI).
- icometrix: Belgium-based AI company with FDA-cleared and CE-marked brain MRI quantification tools (icoBrain) for multiple sclerosis, dementia, and traumatic brain injury. Closely comparable to LPIXEL's EIRL Brain Aneurysm in modality (brain MRI), regulatory pathway (SaMD), and clinical use case (neuroimaging decision support).
- HeartFlow: US-based AI SaMD company analyzing coronary CT angiography for non-invasive FFR assessment. Comparable as a regulated imaging-AI SaMD with similar enterprise hospital sales motion, large PMA/FDA-cleared product portfolio, and reliance on CT scanner-installed-base partnerships.
- Arterys: US-based cloud-native medical imaging AI platform with FDA-cleared products for cardiac MRI, lung CT, and oncology workflows. Comparable to LPIXEL as a multi-modality cloud imaging AI platform selling to radiology departments through enterprise and PACS channels.
Broad incumbents
- Aidoc: Israel-based medical imaging AI platform with broad multi-modality FDA-cleared products covering CT, X-ray, and MRI triage and workflow across numerous clinical indications. Competes with LPIXEL's EIRL suite in modality breadth and hospital enterprise sales motion, but at much larger scale (Series D+ funding, global footprint).
- Viz.ai: US-based AI company specializing in clinical workflow AI for stroke and other time-sensitive conditions, with FDA-cleared products integrated into hospital imaging platforms. Comparable to LPIXEL as a regulated medical imaging AI company selling into enterprise health systems via PACS/workflow integrations, though narrower in modality focus.
- RapidAI: US-based medical imaging AI company with FDA-cleared products for stroke, aneurysm, and PE imaging analysis on CT/MRI. Directly comparable in regulatory pathway (SaMD clearances), modality overlap (brain aneurysm detection), and enterprise radiology channel to LPIXEL's EIRL Brain Aneurysm.
Emerging players
- CureMetrix: US-based AI company with FDA-cleared mammography AI for breast cancer detection (cmTriage, cmAssist). Adjacent comparable to LPIXEL via the EIRL AI Partner Program's FathomX mammography integration, sharing the same regulated mammography SaMD category and women's imaging customer base.
Market position
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
LPIXEL social profiles
Digital presenceLPIXEL financial estimates
Financial estimateRevenue estimate
Valuation estimate
LPIXEL leadership team
Management profileNumber of profiles
Profiles8 records
LPIXEL subsidiaries and ownership
Company hierarchySubsidiaries2 records
LPIXEL funding detail
Funding detailFunding overview
Funding rounds6 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LPIXEL M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LPIXEL
What does LPIXEL do?
LPIXEL develops and sells AI-powered medical image diagnostic support software (EIRL series) covering brain MRI, chest X-ray, chest CT, and colonoscopy analysis for hospitals and clinics, as well as the IMACEL cloud platform for AI-assisted drug discovery research and ImaChek for image integrity checking in scientific publications. Products are deployed as regulated Software as a Medical Device (SaMD) with PMDA approval, EN ISO 13485:2016 certification, and integrations with PACS, medical imaging equipment, and cloud platforms.
Is LPIXEL a public or private company?
LPIXEL is a private company. It is classified as venture growth investor backed and is currently operating.
When was LPIXEL founded?
LPIXEL was founded in 2014. It employs 11 to 50 people.
Where is LPIXEL based?
LPIXEL is headquartered in Otemachi, Japan, in the Asia region.
How does LPIXEL make money?
Three revenue lines are on record. SaaS Subscription is the primary driver. The others are per-Case Pricing and medical Device Sales.
Who are LPIXEL's main competitors?
Direct peers on record are AI Medical Service, icometrix, HeartFlow and Arterys. Broad incumbents are Aidoc, Viz.ai and RapidAI. CureMetrix is listed as an emerging player.
Does LPIXEL have an API?
No public API is recorded for LPIXEL.
What industry is LPIXEL in?
LPIXEL's product category is Medical Imaging AI / Diagnostic Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 33451 and its SIC code is 3841.